Viracta
Founded Year
2007Stage
Reverse Merger | IPOTotal Raised
$142.82MMarket Cap
0.06BStock Price
1.47About Viracta
Viracta (NASDAQ: VIRX) operates as a clinical-stage drug development company. It focuses on a proprietary viral activation therapy platform to address cancers associated with the Epstein-Barr virus (EBV) and additional virus-associated diseases. It develops new medicines to benefit patients with virus-associated cancers and other diseases. It was formerly known as Hemaquest Pharmaceuticals. The company was founded in 2007 and is based in Cardiff, California. In November 2020, Viracta merged with Sunesis Pharmaceuticals.
Missing: Viracta's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Viracta's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Viracta
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Viracta is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Viracta Patents
Viracta has filed 15 patents.
The 3 most popular patent topics include:
- Experimental cancer drugs
- Clusters of differentiation
- Histone deacetylase inhibitors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/8/2020 | 3/23/2021 | Histone deacetylase inhibitors, Antineoplastic drugs, Transcription factors, Orphan drugs, Experimental cancer drugs | Grant |
Application Date | 7/8/2020 |
|---|---|
Grant Date | 3/23/2021 |
Title | |
Related Topics | Histone deacetylase inhibitors, Antineoplastic drugs, Transcription factors, Orphan drugs, Experimental cancer drugs |
Status | Grant |
Latest Viracta News
May 31, 2023
San Diego, California, UNITED STATES SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:00 p.m. EDT. A live webcast of the presentation will be available on the Investors section of the Viracta website under " Events and Webcasts " and archived for 90 days. About Viracta Therapeutics, Inc. Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other advanced EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers. For additional information please visit www.viracta.com . Investor Relations Contact:
Viracta Frequently Asked Questions (FAQ)
When was Viracta founded?
Viracta was founded in 2007.
Where is Viracta's headquarters?
Viracta's headquarters is located at 2533 South. Coast Highway 101, Cardiff.
What is Viracta's latest funding round?
Viracta's latest funding round is Reverse Merger.
How much did Viracta raise?
Viracta raised a total of $142.82M.
Who are the investors of Viracta?
Investors of Viracta include Sunesis Pharmaceuticals, Latterell Venture Partners, Taiwania Capital, aMoon Fund, LifeSci Venture Partners and 11 more.
Who are Viracta's competitors?
Competitors of Viracta include Kiadis Pharma, Adastra Pharmaceuticals, Selexys Pharmaceuticals, Nps Pharmaceuticals, Akebia Therapeutics and 10 more.
Compare Viracta to Competitors
Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on the discovery and development of compounds that inhibit prolyl hydroxylase enzymes.
Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Affinium Pharmaceuticals is a specialty pharmaceutical company developing a class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, the company's lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.
Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.